Department of Dermatology, Saudi German Hospitals and Clinics, Opposite Burj Al Arab, Dubai, United Arab Emirates.
An Bras Dermatol. 2022 Jul-Aug;97(4):471-477. doi: 10.1016/j.abd.2021.10.002. Epub 2022 May 27.
Psoriasis is a chronic inflammatory dermatological disorder characterized by white scales and clearly demarcated erythematous plaques. The prevalence of psoriasis varies from country to country and can occur at any age, implying that ethnicity, environmental factors, and genetic background all play a role in its onset. According to the World Psoriasis Day Consortium, 125 million people globally and 2%-3% of the overall community have psoriasis. The introduction of biological treatments has revolutionized the treatment of moderate to severe psoriasis. These novel drugs, particularly those targeting interleukin (IL)-17 and IL-23p19, can help most patients with psoriasis achieve clear or virtually clear skin with satisfactory durability. Nevertheless, none of these modern treatments are not entirely remedial in their current form, and alarmingly, a limited but growing proportion of patients with severe psoriasis are not responding satisfactorily to currently available treatments. Stem cell therapy, including regulatory T-cells, hematopoietic stem cell transplantation, and mesenchymal stromal cells, has been used in patients with recalcitrant psoriasis. This review discusses the stem cell treatments available for psoriasis.
银屑病是一种慢性炎症性皮肤病,其特征为白色鳞屑和明显分界的红斑。银屑病的患病率因国家而异,可发生于任何年龄,这表明种族、环境因素和遗传背景都在其发病中起作用。根据世界银屑病日联盟的数据,全球有 1.25 亿人患有银屑病,占总人口的 2%-3%。生物治疗的出现彻底改变了中重度银屑病的治疗方式。这些新型药物,特别是针对白细胞介素(IL)-17 和 IL-23p19 的药物,可帮助大多数银屑病患者实现皮肤清晰或几乎清晰,且具有令人满意的持久性。然而,这些现代治疗方法并非完全有效,而且令人担忧的是,目前严重银屑病患者中,有一部分比例对现有治疗方法的反应并不满意。包括调节性 T 细胞、造血干细胞移植和间充质基质细胞在内的干细胞疗法已应用于难治性银屑病患者。本文讨论了用于银屑病的干细胞治疗方法。